The Potential Impact of Clindamycin on Neurosurgery Patients.

• Status: Completed
• Trial end date: 2023-12-30
• Target enrollment: 0
• Participant gender: All

Summary

A prospective, open-label, single center, controlled trial. 44 patients that underwent neurosurgery or presented meningitis signs, for whom Clindamycin add-on therapy to assess its effect on neurological complication in relation to Neuron-specific enolase (NSE) and Neurotensin biomarkers levels.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Treatments: Clindamycin; Clindamycin palmitate; Clindamycin phosphate

Criteria

Inclusion criteria

1) Adult patients will be enrolled if they underwent neurosurgery or presented with clinical signs of meningitis.

Exclusion criteria

1. Age lower than 18.

2. Females with a positive pregnancy test.

3. Known congestive heart failure or ischemic heart disease.

4. Any injury that disturbs the examination (high cervical cord injury or locked-in syndrome, could be a source of bias).

5. Severe brain disease (For example CVA history or brain tumor).

6. Renal failure with GFR lower than 60 ml/min.

7. Patients with unknown identity.